XML 28 R18.htm IDEA: XBRL DOCUMENT v3.7.0.1
License and Collaboration Agreements (Tables)
 3 Months Ended
Mar. 31, 2017
Organization Consolidation And Presentation Of Financial Statements [Abstract]  
License, Collaboration and Other Revenue

In accordance with our collaboration agreements, we recognized license, collaboration and other revenue as follows (in thousands):

 

 

 

 

 

Three months ended March 31,

 

Partner

 

Drug or Drug Candidate

 

2017

 

 

2016

 

AstraZeneca AB

 

MOVANTIK®

and MOVANTIK® fixed-dose

combination program

 

$

3,000

 

 

$

28,000

 

Amgen, Inc.

 

Neulasta®

 

 

1,250

 

 

 

1,250

 

Bayer Healthcare LLC

 

BAY41-6551

(Amikacin Inhale)

 

 

357

 

 

 

357

 

Daiichi Sankyo Europe GmbH

 

ONZEALDTM (NKTR-102)

 

 

216

 

 

 

—

 

Roche

 

MIRCERA®

 

 

—

 

 

 

1,929

 

Baxalta Incorporated

 

ADYNOVATE®

 

 

—

 

 

 

104

 

Other

 

 

 

 

1,269

 

 

 

2,547

 

License, collaboration and other revenue

 

 

 

$

6,092

 

 

$

34,187